Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

Guggenheim analyst Vamil Divan has reiterated a Buy rating on AbbVie (NYSE: ABBV) and has maintained a price target of $288 for the stock. This endorsement reflects confidence in AbbVie's performance and potential in the market.